AHA shares proposals to lower Medicare drug prices with Congress
In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Perspective
Congress returned to Washington this week with a full plate of issues to contend with in the short-term as it defines its legislative agenda for the remainder…
Headline
The House Energy and Commerce Subcommittee on Health held a hearing Jan. 8 to discuss legislation on Medicare payment policies for seniors, including the AHA-…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…